Telehealth Controlled Substance Prescribing in 2026: DEA Rules for TRT

Testosterone is a Schedule III controlled substance, which means every telehealth TRT clinic operates inside the DEA’s telemedicine framework whether it knows it or not. That framework has changed every year since 2023, and the rules in effect today are a blend of statute, temporary flexibilities and a special-registration structure that was still being finalized as 2026 opened. This is what the operating team checks before any clinic writes its first prescription.

The statute underneath everything: Ryan Haight

The Ryan Haight Online Pharmacy Consumer Protection Act (2008) requires at least one in-person medical evaluation before a practitioner prescribes a controlled substance via the internet, unless an exception applies. The exceptions written into the statute (hospital-based telemedicine, practice in the physical presence of a DEA registrant, Indian Health Service, public health emergencies, and a “special registration” the DEA was told to create) were narrow. For fifteen years the special registration did not exist, which is why the COVID-era flexibilities mattered so much to telehealth hormone clinics.

What changed from 2020 to 2026

• 2020–2023: The public health emergency allowed controlled-substance prescribing via telemedicine without a prior in-person exam.
• 2023–2025: The DEA extended those flexibilities three times, most recently through the end of 2025, while it worked on permanent rules.
• January 2025: The DEA published a proposed special registration framework with three categories: a Telemedicine Prescribing Registration (Schedule III–V for most clinicians), an Advanced Telemedicine Prescribing Registration (Schedule II–V for specified specialists), and a Telemedicine Platform Registration for platforms that facilitate prescribing.
• 2026: The practical status of those flexibilities and the special registration is the single most important compliance fact to verify this quarter. Check the DEA’s telemedicine page and talk to counsel; do not rely on a blog post, including this one.

The operating rule in our clinics is conservative: assume the strictest reading that could apply on the date of the visit, and build workflows that satisfy it. That way a rule change tightens nothing you have not already done.

Why testosterone (Schedule III) is the manageable case

Schedule III sits in the category the proposed special registration treats most permissively. Under the proposed framework, a general practitioner would register for Schedule III–V telemedicine prescribing, while Schedule II would be reserved for specific specialties and limited volumes. For a hormone clinic that means testosterone cypionate, enanthate, gels and compounded testosterone are squarely in scope, while Schedule II products (not typical in hormone optimization) are out of scope for most. Non-controlled products — estradiol, progesterone, thyroid hormone, most peptides, anastrozole, clomiphene and enclomiphene — are not touched by Ryan Haight at all, though state telehealth and standard-of-care rules still apply.

State-by-state DEA registration

A detail that surprises many new clinic owners: the DEA expects a separate registration for each state in which you prescribe controlled substances, because registration is tied to a principal place of practice in that state. Practically, that means:

1. Hold the state license first.
2. Obtain the state controlled-substance registration (CSR) where the state requires one, since the DEA will not issue a registration in a state that requires a CSR you do not hold.
3. Apply for the DEA registration for that state (fee currently in the high $800s for three years).
4. Enroll in that state’s PDMP and check it before each controlled-substance prescription where mandated.

At roughly $300 per year per state for the DEA alone, this is a line item in your expansion budget, which is why the Institute’s compliance guide for telemedicine hormone clinics treats DEA, CSR and licensure as one bundle per state.

Workflow requirements that satisfy any version of the rule

• Audio-video first visits. Every proposed and temporary rule has required a real-time, two-way audio-video encounter before a controlled-substance prescription. Audio-only does not qualify for a new TRT patient.
• Identity verification. Government photo ID captured in intake, matched on camera at the first visit, stored in the chart.
• Documented medical necessity. Two morning total testosterone values below your documented threshold plus symptoms, following a published guideline, with the reasoning in the note.
• PDMP check logged. Date, state and result in the note.
• Prescriber-pharmacy consistency. E-prescribe controlled substances (EPCS) through a certified system with two-factor authentication; most states now mandate it.
• Patient location recorded at every visit, since both the DEA registration and the state license are location-dependent.
• Nationwide PDMP and in-person flags. If a special registration takes effect with an in-person or periodic evaluation requirement, your scheduling system must be able to flag the due date.

These steps live inside your visit template and your EHR, which is why the clinic operations playbook builds them into the standard TRT encounter rather than treating them as a separate compliance task.

Compounded testosterone and the pharmacy side

Compounded testosterone from a 503A pharmacy is still Schedule III, and the pharmacy will verify your DEA number for the patient’s state before filling. A pharmacy that fills a controlled substance without that verification is a pharmacy you do not want. Confirm the pharmacy is licensed to ship into each state you serve; that list is shorter than most clinics assume.

FAQ

Can I start a new patient on testosterone with a video visit only in 2026?

It depends on the status of the DEA’s flexibilities and special registration on the date of the visit, and on your state’s telehealth rules. Verify both before launch and quarterly afterward, and document which authority you relied on in the chart.

Do I need a DEA registration in every state I serve?

For controlled substances, the DEA’s position is that you need a registration associated with each state where you prescribe. Non-controlled hormone therapy does not require a DEA registration, but still requires a state license — confirm with counsel for your situation.

Does the special registration replace my state license?

No. A federal special registration, when in effect, sits on top of your state license, state CSR and state telehealth rules. It never substitutes for any of them.